@article{bde3db3a0d6746a9ab3ea37a1dfbd659,
title = "Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients",
abstract = "Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.",
keywords = "Cisplatin, 5-Fluorouracil, 頑固性胃癌, leucovorin, Fluorouracil, Cisplatin, 5-Fluorouracil, Leucovorin, Refractory Gastric Cancer, Fluorouracil",
author = "陳榮楷 and 吳秋文 and 林增熙 and 季匡華 and 趙毅 and 黃以信 and 吳銘芳 and 陳育民 and 劉敏 and 彭汪嘉康 and 李壽東 and 雷永耀",
year = "1994",
doi = "10.6316/TRO/199401(3)255",
language = "English",
volume = "1",
pages = "255--262",
journal = "放射治療與腫瘤學",
issn = "1023-988x",
publisher = "台灣放射腫瘤學會",
number = "3",
}